Label change record
Every change to the wording this site quotes from the FDA labels for eight GLP-1 medicines since January 2024: where and how to inject, the dose schedule, dose increases, missed doses and storage out of the fridge. Across 72 label versions, 38 changed that wording. Each change below is quoted word for word from the archived label on DailyMed.
How it is made: every version of each label is downloaded from DailyMed's archive and compared with the version before it. Only sentences on those topics are compared, and wording that differs only in spacing, punctuation or section numbers is treated as unchanged. Under each changed sentence is its topic and, where the per-pen card quotes lines on that topic, which card lines it touches. It reports what the label text says; it does not interpret it. Last refreshed October 6, 2026. The full record is published as data for anyone to check or cite.
Ozempic (semaglutide)
6 label versions since January 2024; 4 changed the wording this site quotes, most recently May 19, 2026.
The per-pen card's lines
- Device (two card lines): changed in one version, most recently May 19, 2026.
- Dose schedule (three card lines): changed in four versions, most recently May 19, 2026.
- Dose increase (four card lines): changed in three versions, most recently May 19, 2026.
- Missed dose (one card line): no change in this period.
- Storage out of fridge (five card lines): changed in two versions, most recently May 19, 2026.
-
May 19, 2026 (label version 19, published on DailyMed May 21, 2026; this version)
No longer in the label
“After first use of the OZEMPIC pen, the pen can be stored for 56 days at controlled room temperature 59°F to 86°F (15°C to 30°C) or in a refrigerator 36°F to 46°F (2°C to 8°C).”“Injection: 2 mg/3 mL (0.68 mg/mL) available in:”“Injection: 4 mg/3 mL (1.34 mg/mL) available in:”“Injection: 8 mg/3 mL (2.68 mg/mL) available in:”“Prior to first use, OZEMPIC should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”“The 2 mg/1.5 mL (1.34 mg/mL) strength is not currently marketed by Novo Nordisk Inc.”“Treatment with OZEMPIC 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA 1c compared to exenatide 2 mg once weekly (see Table 5 ).”
New in the label
- “After first use of the OZEMPIC pen, the pen can be stored for 56 days at controlled room temperature 15°C to 30°C (59°F to 86°F) or in a refrigerator 2°C to 8°C (36°F to 46°F).”
- “Choose Your Injection Site”
- “Clean the injection site with an alcohol wipe and allow to dry.”
- “If blood appears at the injection site, lightly press with a cotton ball or gauze over it, without rubbing.”
- “If needed, the prefilled syringes can be stored out of the refrigerator between 46°F to 86°F (8°C to 30°C) for up to 28 days.”
- “Injection: 0.25 mg, 0.5 mg or 1 mg per 0.5 mL in a single-dose prefilled syringe ( 3 )”
- “Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens ( 3 )”
- “Pinch and hold a fold of skin at the injection site between your thumb and fingers.”
- “Population PK model also included maintenance dose and injection site as covariates.”
- “Prior to first use, the OZEMPIC pen should be stored in a refrigerator between 2°C to 8°C (36°F to 46°F).”
- “Record the date your prefilled syringe was removed from the refrigerator and dispose of it, if not used within 28 days.”
- “Store the OZEMPIC prefilled syringe refrigerated at 2°C to 8°C (36°F to 46°F).”
- “Store the unused OZEMPIC prefilled syringes in the refrigerator between 36°F to 46°F (2°C to 8°C).”
- “Your healthcare provider can help you choose the injection site that is best for you.”
-
October 14, 2025 (label version 18, published on DailyMed Jan 26, 2026; this version)
No longer in the label
“In each case, inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration (”“In each case, patients can then resume their regular once weekly dosing schedule.”“In patients with type 2 diabetes, the mean population-PK estimated steady-state concentrations following once weekly subcutaneous administration of 0.5 mg and 1 mg semaglutide were approximately 65 ng/mL and 123 ng/mL, respectively.”
New in the label
- “Treatment with OZEMPIC 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA 1c compared to exenatide 2 mg once weekly (see Table 5 ).”
- “Treatment with OZEMPIC 2 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA 1c compared with OZEMPIC 1 mg (see Table”
-
October 14, 2025 (label version 17, published on DailyMed Nov 17, 2025; this version)
No longer in the label
“To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage ( 1 , 2.2 ).”
New in the label
- “To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage.”
-
January 2, 2025 (label version 16, published on DailyMed Feb 10, 2025; this version)
No longer in the label
“If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dosage, the dosage may be increased to 1 mg once weekly.”“If additional glycemic control is needed after at least 4 weeks on the 1 mg dosage, the dosage may be increased to 2 mg once weekly.”“In each case, inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.2 )] .”“In patients with type 2 diabetes, the mean population-PK estimated steady-state concentrations following once weekly subcutaneous administration of 0.5 mg and 1 mg semaglutide were approximately 65.0 ng/mL and 123.0 ng/mL, respectively.”“Inject OZEMPIC subcutaneously to the abdomen, thigh, or upper arm.”“Prior to first use, OZEMPIC should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC) (Table 10).”“Treatment with OZEMPIC 0.5 mg and 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA 1c compared to sitagliptin (see Table 4 and Figure 5).”“Treatment with OZEMPIC 1 mg once weekly for 56 weeks resulted in a statistically significant reduction in HbA 1c compared to exenatide 2 mg once weekly (see Table 5).”“Treatment with OZEMPIC 2 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA 1c compared with OZEMPIC 1 mg (see Table 7).”
New in the label
- “0.5 mg dosage, the dosage may be increased to 1 mg once weekly.”
- “1 mg dosage, the dosage may be increased to 2 mg once weekly.”
- “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.7 ), Adverse Reactions ( 6.1 )].”
- “In each case, inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration (”
- “In patients with type 2 diabetes, the mean population-PK estimated steady-state concentrations following once weekly subcutaneous administration of 0.5 mg and 1 mg semaglutide were approximately 65 ng/mL and 123 ng/mL, respectively.”
- “Increase the dosage to the maintenance dosage, 1 mg once weekly, after at least 4 weeks on the 0.5 mg dosage.”
- “Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm.”
- “Prior to first use, OZEMPIC should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”
- “Recommended Maintenance Dosage in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease”
- “Recommended Maintenance and Maximum Dosages for Glycemic Control”
- “The recommended maintenance dosage is 0.5 mg, 1 mg, or 2 mg, injected subcutaneously once weekly, based on glycemic control.”
- “To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage ( 1 , 2.2 ).”
Wegovy (semaglutide)
13 label versions since January 2024; 8 changed the wording this site quotes, most recently June 18, 2026.
The per-pen card's lines
- Device (four card lines): changed in three versions, most recently June 18, 2026.
- Dose schedule (three card lines): changed in eight versions, most recently June 18, 2026.
- Dose increase (seven card lines): changed in six versions, most recently June 18, 2026.
- Missed dose (two card lines): changed in six versions, most recently June 18, 2026.
- Storage out of fridge (six card lines): changed in four versions, most recently June 18, 2026.
-
June 18, 2026 (label version 19, published on DailyMed Jun 30, 2026; this version)
No longer in the label
“Do not store WEGOVY injection in the freezer or directly adjacent to the refrigerator cooling element.”“If 2 or more consecutive doses of WEGOVY injection are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY injection and follow the dosage escalation schedule, which may reduce the occurrence of gastrointestinal adverse reactions associated with reinitiation of treatment [see Dosage and Administration ( 2.2 )].”“If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”“If you miss doses of WEGOVY for 2 or more weeks, take your next dose on the regularly scheduled day or call your healthcare provider to talk about how to restart your treatment.”“The maintenance dosage of WEGOVY injection for weight reduction in pediatric patients aged 12 years and older is either 2.4 mg (recommended), 1.7 mg once weekly.”“Throw away the pen if WEGOVY has been frozen, has been exposed to light or temperatures above 86°F (30°C), has been out of the refrigerator for 28 days or longer, or after use.”
New in the label
- “0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, or 7.2 mg/0.75 mL (WEGOVY HD) in a single-dose pen”
- “0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, or 2.4 mg/0.75 mL in a single-dose syringe”
- “9.6 mg/3 mL (3.2 mg/mL)”
- “9.6 mg/3 mL (3.2 mg/mL) solution in a single-patient-use pen (WEGOVY FlexTouch) that delivers four 2.4 mg/0.75 mL doses”
- “After first use, WEGOVY FlexTouch single-patient-use pen can be stored for 56 days between 15°C to 30°C (59°F to 86°F) or in a refrigerator 2°C to 8°C (36°F to 46°F).”
- “After first use, store WEGOVY FlexTouch between 68°F to 77°F (20°C to 25°C) or in a refrigerator 36°F to 46°F (2°C to 8°C) for up to 56 days.”
- “After first use, store WEGOVY FlexTouch pen between 59°F to 86°F (15°C to 30°C) or in the refrigerator between 36°F to 46°F (2°C to 8°C) for up to 56 days.”
- “Choose an injection site on your upper arms, stomach or upper legs.”
- “Do not store WEGOVY in the freezer or directly adjacent to the refrigerator cooling element.”
- “If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration ( 2.2 ), Warnings and Precautions (”
- “If blood appears at the injection site, press the site lightly with a cotton ball or gauze.”
- “If you miss a dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”
- “If you miss doses of WEGOVY for 2 or more consecutive weeks, contact your healthcare provider to talk about how to restart your treatment.”
- “Let the injection site dry before you inject your dose.”
- “Prior to first use, store WEGOVY FlexTouch single-patient-use pen in a refrigerator between 2°C to 8°C (36°F to 46°F).”
- “Store in the refrigerator between 36°F to 46°F (2°C to 8°C).”
- “The maintenance dosage of WEGOVY injection for weight reduction in pediatric patients aged 12 years and older is either 2.4 mg (recommended), or 1.7 mg once weekly.”
- “Throw away if the WEGOVY FlexTouch pen if it has been frozen, has been exposed to light or temperatures above 86°F (30°C), or has been out of the refrigerator for 56 days or longer.”
- “Throw away if the single-patient-use WEGOVY FlexTouch pen has been frozen, has been exposed to light or temperatures above 86°F (30°C), or has been out of the refrigerator for 56 days or longer.”
- “Throw away the WEGOVY single-dose pen or syringe if it has been frozen, has been exposed to light or temperatures above 86°F (30°C), has been out of the refrigerator for 28 days or longer, or after use.”
- “Use Wegovy FlexTouch Once Weekly”
- “You may inject in the same body area each week, but make sure it is not in the same spot used for the last injection.”
-
May 5, 2026 (label version 18, published on DailyMed May 22, 2026; this version)
No longer in the label
“7.2 mg/0.75 mL (WEGOVY HD)”“Do not store WEGOVY in the freezer or directly adjacent to the refrigerator cooling element.”“Store the WEGOVY single-dose pen in the refrigerator from 2°C to 8°C (36°F to 46°F).”“WEGOVY Injection (2.4 mg once weekly)”
New in the label
- “(2.4 mg Once Weekly)”
- “Clean the injection site with an alcohol wipe and allow to dry.”
- “Do not store WEGOVY injection in the freezer or directly adjacent to the refrigerator cooling element.”
- “If blood appears at the injection site, lightly press with a cotton ball or gauze over it, without rubbing.”
- “If needed, the prefilled syringes can be stored out of the refrigerator between 46°F to 86°F (8°C to 30°C) for up to 28 days.”
- “Once Daily Tablet Dosage”
- “Pinch and hold a fold of skin at the injection site between your thumb and fingers.”
- “Record the date your prefilled syringe was removed from the refrigerator and dispose of it if not used within 28 days.”
- “Store the WEGOVY prefilled single-dose pen or single-dose syringe in the refrigerator from 2°C to 8°C (36°F to 46°F).”
- “Store the unused WEGOVY prefilled syringes in the refrigerator between 36°F to 46°F (2°C to 8°C).”
-
March 19, 2026 (label version 17, published on DailyMed Apr 02, 2026; this version)
No longer in the label
“Recommended Maintenance Dosage of WEGOVY Injection for Approved Indications”“Store WEGOVY tablets at room temperature between 68°F and 77°F (20°C to 25°C).”“The maintenance dosage of WEGOVY injection for weight reduction in adults and pediatric patients aged 12 years and older is either 2.4 mg (recommended) or 1.7 mg once weekly.”
New in the label
- “7.2 mg/0.75 mL (WEGOVY HD)”
- “After dosage escalation, 1,149 patients received at least one dose of WEGOVY 7.2 mg injection, and 578 patients received 7.2 mg for at least 1 year.”
- “Consider reescalation to 2.4 mg once weekly [see Adverse Reactions (”
- “Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (”
- “Do not store WEGOVY in the freezer or directly adjacent to the refrigerator cooling element.”
- “Do not store WEGOVY in the freezer or directly beside the refrigerator cooling element.”
- “For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.”
- “Of the patients who recovered after action taken with WEGOVY, 38 patients were re-escalated to 7.2 mg.”
- “Recommended Maintenance Dosage of WEGOVY Injection for All Approved Indications”
- “Store WEGOVY tablets at room temperature between 68°F to 77°F (20°C to 25°C).”
- “The average semaglutide steady state concentration following subcutaneous administration of WEGOVY 7.2 mg once weekly injection was approximately 230 nmol/L in patients with obesity (BMI greater than or equal to 30 kg/m 2 ).”
- “The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly.”
- “The maintenance dosage of WEGOVY injection for weight reduction in pediatric patients aged 12 years and older is either 2.4 mg (recommended), 1.7 mg once weekly.”
- “Throw away the pen if WEGOVY has been frozen, has been exposed to light or temperatures above 86°F (30°C), has been out of the refrigerator for 28 days or longer, or after use.”
- “Throw away the pen if WEGOVY has been frozen, has been exposed to light or temperatures above 86°F (30°C), or has been out of the refrigerator for 28 days or longer or after use.”
- “WEGOVY Injection (2.4 mg once weekly)”
- “WEGOVY Injection (7.2 mg once weekly)”
- “to reduce excess body weight and maintain weight reduction long term with the 7.2 mg once weekly dosage.”
-
December 22, 2025 (label version 14, published on DailyMed Jan 06, 2026; this version)
No longer in the label
“2.2 Recommended Dosage Initiation and Escalation Schedule”“2.3 Recommended Maintenance Dosage”“2.4 Recommendations Regarding Missed Dose”“Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals.”“Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals.”“All patients received WEGOVY during the run-in period of 20 weeks that included 16 weeks of dose escalation.”“Follow the recommended dosage initiation and escalation in Table 1 for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”“For all other indications except for MASH treatment, the maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly.”“For patients with MASH, the maintenance dosage of WEGOVY is 2.4 mg once weekly.”“If 2 or more consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment.”“If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”“If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”“If you miss 1 dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”“Inform patients if a dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”“Inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.4 )] .”“Initiate WEGOVY with a dosage of 0.25 mg injected subcutaneously once weekly.”“Recommended Dosage Initiation and Escalation”“Recommended Dosage Initiation and Escalation Schedule,”“Recommended Maintenance Dosage ( 2.2 , 2.3 ) ………………….08/2025”“See indication below (Subsection 2.3) for maintenance dosage”“The maintenance dosage of WEGOVY for CV risk reduction and weight reduction is either 2.4 mg (recommended) or 1.7 mg injected subcutaneously once weekly.”“The recommended dosage of WEGOVY in patients with hepatic impairment is the same as those with normal hepatic function.”“The recommended maintenance dosage of WEGOVY for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis is 2.4 mg injected subcutaneously once weekly.”“The time of day and the injection site can be changed without dose adjustment.”“The use of WEGOVY (semaglutide 2.4 mg or 1.7 mg once weekly) in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated.”“Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage.”
New in the label
- “2.2 Recommended Dosage for WEGOVY Injection”
- “2.3 Recommended Dosage of WEGOVY Tablets”
- “2.4 Recommendations Regarding Missed Dose(s)”
- “Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals.”
- “Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”
- “All patients received WEGOVY injection during the run-in period of 20 weeks that included 16 weeks of dose escalation.”
- “Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”
- “Follow the dosage escalation in Table 2 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”
- “If 2 or more consecutive doses of WEGOVY injection are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY injection and follow the dosage escalation schedule, which may reduce the occurrence of gastrointestinal adverse reactions associated with reinitiation of treatment [see Dosage and Administration ( 2.2 )].”
- “If a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day.”
- “If additional weight reduction is needed in patients with type 2 diabetes mellitus treated with WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection and follow the recommended dosage escalation for WEGOVY injection. [see Dosage and Administration ( 2.2 ), Use in Specific Populations ( 8.6 ), and Clinical Pharmacology ( 12.3 )].”
- “If one dose of WEGOVY injection is missed and the next scheduled dose is:”
- “If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation.”
- “If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY injection 1.7 mg once weekly [see Dosage and Administration ( 2.5 )] .”
- “If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”
- “If you miss a dose of WEGOVY, skip the missed dose and go back to your regular schedule for the next dose.”
- “In patients with type 2 diabetes, the average semaglutide blood concentrations following administration of WEGOVY 25 mg tablets once daily were lower than the average semaglutide blood concentrations following use of WEGOVY 2.4 mg injection once weekly [see Clinical Pharmacology ( 12.3 )] .”
- “In patients without type 2 diabetes, the average semaglutide blood concentrations following administration of WEGOVY 25 mg tablets once daily or WEGOVY 2.4 mg injection once weekly were similar.”
- “Inform patients if a dose of WEGOVY injection is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY injection as soon as possible.”
- “Inform patients if a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day [see Dosage and Administration ( 2.4 )] .”
- “Initiate WEGOVY tablet with a dosage of 1.5 mg once daily for 30 days.”
- “One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”
- “Patients who could not tolerate the recommended escalation dosage, could stay at a lower dose level.”
- “Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults”
- “Recommended Maintenance Dosage of WEGOVY Injection for Approved Indications”
- “Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications”
- “Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications in Adults and Pediatric Patients Aged 12 Years and Older”
- “Refer to the full PI for maintenance dosages based on the indication.”
- “See the indication below for the recommended maintenance dosage(s)”
- “Store WEGOVY tablets at room temperature between 68°F and 77°F (20°C to 25°C).”
- “Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].”
- “Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces).”
- “The average semaglutide steady state concentration following subcutaneous administration of WEGOVY 2.4 mg once weekly was approximately 68 nmol/L in patients with type 2 diabetes and obesity or overweight (BMI greater than or equal to 27 kg/m 2 ).”
- “The average semaglutide steady state concentration following subcutaneous administration of WEGOVY 2.4 mg once weekly was approximately 75 nmol/L in patients with obesity or overweight (BMI greater than or equal to 27 kg/m 2 ).”
- “The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly.”
- “The maintenance dosage of WEGOVY injection for cardiovascular risk reduction in adults is either 2.4 mg (recommended) or 1.7 mg once weekly.”
- “The maintenance dosage of WEGOVY injection for weight reduction in adults and pediatric patients aged 12 years and older is either 2.4 mg (recommended) or 1.7 mg once weekly.”
- “The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly.”
- “The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily for cardiovascular risk reduction and weight reduction in adults”
- “The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily.”
- “The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly.”
- “The recommended starting dosage of WEGOVY tablets is 1.5 mg taken orally once daily.”
- “The steady-state concentrations increased approximately proportionally with doses up to 25 mg once daily.”
- “The time of day and the injection site can be changed without the need for a dosage modification.”
- “The usual recommended maintenance dosage of WEGOVY injection is 2.4 mg once weekly.”
- “Then follow the dosage escalation schedule in Table 1, titrating every 4 weeks to achieve the maintenance dosage.”
- “Then follow the dosage escalation schedule, titrating every 30 days to achieve the maintenance dosage.”
-
November 21, 2025 (label version 13, published on DailyMed Dec 05, 2025; this version)
No longer in the label
“If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”
New in the label
- “If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”
- “If you miss 1 dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”
- “Inform patients if a dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”
- “Inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.4 )] .”
- “Initiate at 0.25 mg once weekly for 4 weeks.”
- “The use of WEGOVY (semaglutide 2.4 mg or 1.7 mg once weekly) in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated.”
-
October 14, 2025 (label version 12, published on DailyMed Nov 17, 2025; this version)
No longer in the label
“Consider reescalation to 2.4 mg once weekly [see Adverse Reactions (”“Dosage and Administration, Recommended Dosage Initiation and Escalation Schedule, Recommended Maintenance Dosage ( 2.2 , 2.3 )……………………… 08/2025”“If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly .”“If you miss 1 dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”“Inform patients if a dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”“Inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.4 )].”“Initiate at 0.25 mg once weekly for 4 weeks.”“Once Weekly Subcutaneous Dosage”“The use of WEGOVY (semaglutide 2.4 mg or 1.7 mg once weekly) in patients with type 1 diabetes mellitus or in combination with insulin has not been evaluated.”
New in the label
- “If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”
- “Recommended Dosage Initiation and Escalation Schedule,”
- “Recommended Maintenance Dosage ( 2.2 , 2.3 ) ………………….08/2025”
-
August 1, 2025 (label version 11, published on DailyMed Aug 29, 2025; this version)
No longer in the label
“2.2 Recommended Dosage in Adults and Pediatric Patients Aged 12 Years and Older”“2.3 Recommendations Regarding Missed Dose”“Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (”“Dosage Initiation and Escalation”“Follow the dosage initiation and escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”“If you miss a dose of WEGOVY and the next schedule dose is less than 2 days away (48 hours), do not administer the dose.”“Recommended Dosage Escalation in Adults and Pediatric Patients Aged 12 Years and Older”“The maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) .”“The maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly.”“Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage (2.2 , 2.3).”
New in the label
- “2.2 Recommended Dosage Initiation and Escalation Schedule”
- “2.3 Recommended Maintenance Dosage”
- “2.4 Recommendations Regarding Missed Dose”
- “Consider reescalation to 2.4 mg once weekly [see Adverse Reactions (”
- “Dosage and Administration, Recommended Dosage Initiation and Escalation Schedule, Recommended Maintenance Dosage ( 2.2 , 2.3 )……………………… 08/2025”
- “Dose escalation could be prolonged or patients could remain at a lower dose if 2.4 mg once weekly was not tolerable.”
- “Follow the recommended dosage initiation and escalation in Table 1 for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”
- “For all other indications, except for MASH treatment, the maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly.”
- “For patients with MASH, the maintenance dosage of WEGOVY is 2.4 mg once weekly.”
- “If patients do not tolerate 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly .”
- “If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”
- “If you miss 1 dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.”
- “Inform patients if a dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible.”
- “Inform patients to resume their regular once weekly dosing schedule [see Dosage and Administration ( 2.4 )].”
- “Recommended Dosage Initiation and Escalation”
- “See indication below (Subsection 2.3) for maintenance dosage”
- “The maintenance dosage of WEGOVY for CV risk reduction and weight reduction is either 2.4 mg (recommended) or 1.7 mg injected subcutaneously once weekly.”
- “The recommended maintenance dosage of WEGOVY for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis is 2.4 mg injected subcutaneously once weekly.”
- “Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage ( 2.2 ).”
-
November 1, 2024 (label version 10, published on DailyMed Dec 12, 2024; this version)
No longer in the label
“2.2 Recommended Dosage in Adults”“2.3 Recommended Dosage in Pediatric Patients Aged 12 Years and Older”“2.4 Recommendations Regarding Missed Dose”“If patients do not tolerate the 2.4 mg once-weekly maintenance dosage, the maintenance dosage may be reduced to 1.7 mg once weekly.”“If you miss doses of WEGOVY for more than 2 weeks, take your next dose on the regularly scheduled day or call your healthcare provider to talk about how to restart your treatment.”“Initiate WEGOVY according to the dosage escalation schedule in Table 2 to minimize gastrointestinal adverse reactions [see Adverse Reactions”“Recommended Dosage Regimen for Adults”“Recommended Dosage Regimen for Pediatric Patients Aged 12 Years and Older”“The 0.25 mg, 0.5 mg, and 1 mg once-weekly dosages are initiation and escalation dosages and are not approved as maintenance dosages.”“The maintenance dosage of WEGOVY in adults is either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) .”“The maintenance dosage of WEGOVY in adults is either 2.4 mg (recommended) or 1.7 mg once weekly.”“The maintenance dosage of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly (2.3).”“The maintenance dosage of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly.”“Then follow the dose escalation schedule presented in Table 1 to minimize gastrointestinal adverse reactions [see Adverse Reactions (”“These reactions increased during dose escalation.”“a Not approved as maintenance dosages”
New in the label
- “2.2 Recommended Dosage in Adults and Pediatric Patients Aged 12 Years and Older”
- “2.3 Recommendations Regarding Missed Dose”
- “Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (”
- “Follow the dosage initiation and escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ), Adverse Reactions ( 6.1 )] .”
- “If you miss doses of WEGOVY for 2 or more weeks, take your next dose on the regularly scheduled day or call your healthcare provider to talk about how to restart your treatment.”
- “Recommended Dosage Escalation in Adults and Pediatric Patients Aged 12 Years and Older”
- “The maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) .”
- “The maintenance dosage of WEGOVY is either 2.4 mg (recommended) or 1.7 mg once weekly.”
- “The recommended dosage of WEGOVY in patients with hepatic impairment is the same as those with normal hepatic function.”
- “These reactions were most frequently reported during dosage escalation.”
Mounjaro (tirzepatide)
15 label versions since January 2024; 8 changed the wording this site quotes, most recently August 27, 2026.
The per-pen card's lines
- Device (two card lines): changed in three versions, most recently August 27, 2026.
- Dose schedule (three card lines): changed in three versions, most recently August 27, 2026.
- Dose increase (two card lines): changed in three versions, most recently August 27, 2026.
- Missed dose (one card line): changed in one version, most recently August 27, 2026.
- Storage out of fridge (two card lines): changed in four versions, most recently August 27, 2026.
-
August 27, 2026 (label version 40, published on DailyMed Sep 02, 2026; this version)
No longer in the label
“After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.”“After 4 weeks, increase to 5 mg injected subcutaneously once weekly.”“Discard single-dose pen and single-dose vial after a total of 21 days at room temperature.”“Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] .”“Inject MOUNJARO subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”“Inject subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”“Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial or single-patient-use KwikPen ® ( 3 )”“Injection: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial ( 3 )”
New in the label
- “Discard the single-dose pen or single-dose vial after a total of 21 days at room temperature.”
- “Follow the starting dosage recommendation and dosage escalation schedule below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )].”
- “Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm.”
- “Inject subcutaneously in the abdomen, thigh, or have another person inject in the back of the upper arm.”
- “Multi-dose vial or single-patient-use KwikPen ® : 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL ( 3 )”
- “Recommendations Regarding Missed Doses”
- “Recommended Starting Dosage and Escalation”
- “Single-dose pen or single-dose vial: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, or 15 mg/0.5 mL ( 3 )”
-
April 22, 2026 (label version 38, published on DailyMed May 06, 2026; this version)
No longer in the label
“If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86⁰F (30⁰C) for up to 21 days.”“If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to 21 days.”“If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab.”“You may store the unopened vial at room temperature up to 86°F (30°C) for up to 21 days.”“You may store your Pen at room temperature up to 86°F (30°C) for up to 21 days.”
New in the label
- “Discard single-dose pen and single-dose vial after a total of 21 days at room temperature.”
- “Discard the Pen after a total of 21 days at room temperature.”
- “Discard the vial after a total of 21 days at room temperature.”
- “If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86⁰F (30⁰C) for up to a total of 21 days.”
- “If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days.”
- “Throw away single-dose pen or single-dose vial after a total of 21 days at room temperature.”
- “You may store the unopened vial at room temperature up to 86°F (30°C) for up to a total of 21 days.”
- “You may store your Pen at room temperature up to 86°F (30°C) for up to a total of 21 days.”
-
January 20, 2026 (label version 35, published on DailyMed Feb 09, 2026; this version)
No longer in the label
“10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses”“20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses”“30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses”“40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses”“50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses”“60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses”“If stored at room temperature [up to 30°C (86°F)], throw away unopened vial after 30 days.”“Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial ( 3 )”“Store multi-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”“Store opened (in-use) vial in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”“Store unopened vial in the refrigerator at 2°C to 8°C (36°F to 46°F).”“The unopened vial can be used until the expiration date on the label if kept in the refrigerator.”“Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medication left in it.”“Throw away the multi-dose vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”
New in the label
- “2.1 Recommended Dosage”
- “Choose an injection site.”
- “If stored at room temperature [up to 30°C (86°F)], throw away unopened multi-dose vial or single-patient-use KwikPen after 30 days.”
- “If you see blood after you pull the needle out of your skin, lightly press the injection site with gauze or a cotton ball.”
- “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial or single-patient-use KwikPen ® ( 3 )”
- “Recommended Dosage ( 2.1 )”
- “Store multi-dose vial or single-patient-use KwikPen in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”
- “Store opened (in-use) multi-dose vial or single-patient-use KwikPen in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”
- “Store unopened multi-dose vial or single-patient-use KwikPen in the refrigerator at 2°C to 8°C (36°F to 46°F).”
- “Store unused Pens in the refrigerator between 36°F to 46°F (2°C to 8°C).”
- “The unopened multi-dose vial or single-patient-use KwikPen can be used until the expiration date on the label if kept in the refrigerator.”
- “Throw away opened multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.”
- “Throw away the multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”
- “Unused Pens may be used until the expiration date (EXP) printed on the label if the Pen has been kept in the refrigerator.”
- “Use MOUNJARO KwikPen once weekly”
- “Write the day of the week you choose to inject.”
- “You may store your used Pen at room temperature up to 86°F (30°C) after your injection.”
- “You or another person can inject the medicine in your thigh or stomach (abdomen) at least 2 inches from the belly button.”
-
January 7, 2026 (label version 34, published on DailyMed Jan 26, 2026; this version)
No longer in the label
“Store MOUNJARO in a refrigerator at 2°C to 8°C (36°F to 46°F).”“Store MOUNJARO in the refrigerator between 36°F to 46°F (2°C to 8°C).”
New in the label
- “10 mg/2.4 mL (4.17 mg/mL)”
- “10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses”
- “20 mg/2.4 mL (8.33 mg/mL)”
- “20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses”
- “30 mg/2.4 mL (12.5 mg/mL)”
- “30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses”
- “4 doses of 10 mg/0.6 mL”
- “4 doses of 12.5 mg/0.6 mL”
- “4 doses of 15 mg/0.6 mL”
- “4 doses of 2.5 mg/0.6 mL”
- “4 doses of 5 mg/0.6 mL”
- “4 doses of 7.5 mg/0.6 mL”
- “40 mg/2.4 mL (16.7 mg/mL)”
- “40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses”
- “50 mg/2.4 mL (20.8 mg/mL)”
- “50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses”
- “60 mg/2.4 mL (25 mg/mL)”
- “60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses”
- “If stored at room temperature [up to 30°C (86°F)], throw away unopened vial after 30 days.”
- “If stored at room temperature [up to 86°F (30°C)], throw away unopened vial after 30 days.”
- “If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze.”
- “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial ( 3 )”
- “It can be used until the expiration date on the label if kept in the refrigerator.”
- “Store MOUNJARO single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F).”
- “Store each single-dose pen or single-dose vial in the refrigerator between 36⁰F to 46⁰F (2⁰C to 8⁰C).”
- “Store multi-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”
- “Store opened (in-use) vial in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”
- “Store opened (in-use) vial in the original carton in the refrigerator at 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”
- “Store unopened vial in the refrigerator at 2°C to 8°C (36°F to 46°F).”
- “Store unopened vial in the refrigerator at 36°F to 46°F (2°C to 8°C).”
- “The unopened vial can be used until the expiration date on the label if kept in the refrigerator.”
- “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medication left in it.”
- “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.”
- “Throw away the multi-dose vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”
-
December 19, 2025 (label version 33, published on DailyMed Dec 31, 2025; this version)
No longer in the label
“Inject subcutaneously in the abdomen, thigh, or upper arm.”“The maximum dosage is 15 mg subcutaneously once weekly.”“The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.”
New in the label
- “10 mg injected subcutaneously once weekly in pediatric patients.”
- “15 mg injected subcutaneously once weekly in adults.”
- “Adults: 15 mg subcutaneously once weekly.”
- “Inject subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”
- “Maximum dosage ( 2.1 ):”
- “Pediatric patients 10 years of age and older: 10 mg subcutaneously once weekly.”
- “The maximum dosage of MOUNJARO is:”
-
October 24, 2025 (label version 31, published on DailyMed Nov 17, 2025; this version)
No longer in the label
“Inject MOUNJARO subcutaneously in the abdomen, thigh, or upper arm.”“Inject MOUNJARO under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”
New in the label
- “Inject MOUNJARO subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”
- “Inject MOUNJARO under the skin (subcutaneously) of your stomach (abdomen), thigh, or another person should inject in the back of the upper arm.”
-
May 28, 2025 (label version 24, published on DailyMed Jun 13, 2025; this version)
No longer in the label
“MOUNJARO is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”
New in the label
- “Inject MOUNJARO under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”
-
November 1, 2024 (label version 18, published on DailyMed Nov 21, 2024; this version)
New in the label
- “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] .”
Zepbound (tirzepatide)
20 label versions since January 2024; 9 changed the wording this site quotes, most recently August 28, 2026.
The per-pen card's lines
- Device (two card lines): changed in five versions, most recently August 28, 2026.
- Dose schedule (four card lines): changed in three versions, most recently January 20, 2026.
- Dose increase (four card lines): changed in two versions, most recently December 20, 2024.
- Missed dose (one card line): changed in two versions, most recently December 20, 2024.
- Storage out of fridge (two card lines): changed in three versions, most recently April 22, 2026.
-
August 28, 2026 (label version 40, published on DailyMed Sep 02, 2026; this version)
No longer in the label
“Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial or single-patient-use KwikPen ® ( 3 )”“Injection: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial ( 3 )”
New in the label
- “Multi-dose vial or single-patient-use KwikPen ® : 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL ( 3 )”
- “Single-dose pen or single-dose vial: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, or 15 mg/0.5 mL ( 3 )”
-
April 22, 2026 (label version 38, published on DailyMed May 06, 2026; this version)
No longer in the label
“Discard single-dose pen and single-dose vial if not used within 21 days after removing from the refrigerator.”“Discard the pen if not used within 21 days after removing from the refrigerator.”“If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86°F (30°C) for up to 21 days.”“If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to 21 days.”“If single-dose pen or single-dose vial is stored at room temperature, it should not be returned to the refrigerator.”“If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab.”“If you store the pen at room temperature, do not return the pen to the refrigerator.”“Throw away single-dose pen or single-dose vial if not used within 21 days after removing from the refrigerator.”“You may store the unopened vial at room temperature up to 86°F (30°C) for up to 21 days.”“You may store your pen at room temperature up to 86°F (30°C) for up to 21 days.”
New in the label
- “Discard single-dose pen and single-dose vial after a total of 21 days at room temperature.”
- “Discard the pen after a total of 21 days at room temperature.”
- “Discard the vial after a total of 21 days at room temperature.”
- “If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86°F (30°C) for up to a total of 21 days.”
- “If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days.”
- “Throw away single-dose pen or single-dose vial after a total of 21 days at room temperature.”
- “You may store the unopened vial at room temperature up to 86°F (30°C) for up to a total of 21 days.”
- “You may store your pen at room temperature up to 86°F (30°C) for up to a total of 21 days.”
-
January 20, 2026 (label version 32, published on DailyMed Feb 05, 2026; this version)
No longer in the label
“10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses”“20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses”“30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses”“40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses”“50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses”“60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses”“If stored at room temperature [up to 30°C (86°F)], throw away unopened vial after 30 days.”“Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial ( 3 )”“Store multi-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”“Store opened (in-use) vial in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”“Store unopened vial in the refrigerator at 2°C to 8°C (36°F to 46°F).”“The unopened vial can be used until the expiration date on the label if kept in the refrigerator.”“Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medication left in it.”“Throw away the multi-dose vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”
New in the label
- “Choose an injection site.”
- “If stored at room temperature [up to 30°C (86°F)], throw away unopened multi-dose vial or single-patient-use KwikPen after 30 days.”
- “If you see blood after you pull the needle out of your skin, lightly press the injection site with gauze or a cotton ball.”
- “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial or single-patient-use KwikPen ® ( 3 )”
- “Store multi-dose vial or single-patient-use KwikPen in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”
- “Store opened (in-use) multi-dose vial or single-patient-use KwikPen in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”
- “Store unopened multi-dose vial or single-patient-use KwikPen in the refrigerator at 2°C to 8°C (36°F to 46°F).”
- “Store unused Pens in the refrigerator between 36°F to 46°F (2°C to 8°C).”
- “The unopened multi-dose vial or single-patient-use KwikPen can be used until the expiration date on the label if kept in the refrigerator.”
- “Throw away opened multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.”
- “Throw away the multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”
- “Unused Pens may be used until the expiration date (EXP) printed on the label if the Pen has been kept in the refrigerator.”
- “Use ZEPBOUND KwikPen once weekly”
- “Write the day of the week you choose to inject.”
- “You may store your used Pen at room temperature up to 86°F (30°C) after your injection.”
- “You or another person can inject the medicine in your thigh or stomach (abdomen) at least 2 inches from the belly button.”
-
January 7, 2026 (label version 31, published on DailyMed Jan 23, 2026; this version)
No longer in the label
“Discard if not used within 21 days after removing from the refrigerator.”“If ZEPBOUND is stored at room temperature, it should not be returned to the refrigerator.”“Store ZEPBOUND in a refrigerator at 2°C to 8°C (36°F to 46°F).”“Store ZEPBOUND in the refrigerator between 36°F to 46°F (2°C to 8°C).”
New in the label
- “10 mg/2.4 mL (4.17 mg/mL)”
- “10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses”
- “20 mg/2.4 mL (8.33 mg/mL)”
- “20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses”
- “30 mg/2.4 mL (12.5 mg/mL)”
- “30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses”
- “4 doses of 10 mg/0.6 mL”
- “4 doses of 12.5 mg/0.6 mL”
- “4 doses of 15 mg/0.6 mL”
- “4 doses of 2.5 mg/0.6 mL”
- “4 doses of 5 mg/0.6 mL”
- “4 doses of 7.5 mg/0.6 mL”
- “40 mg/2.4 mL (16.7 mg/mL)”
- “40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses”
- “50 mg/2.4 mL (20.8 mg/mL)”
- “50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses”
- “60 mg/2.4 mL (25 mg/mL)”
- “60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses”
- “Discard single-dose pen and single-dose vial if not used within 21 days after removing from the refrigerator.”
- “If single-dose pen or single-dose vial is stored at room temperature, it should not be returned to the refrigerator.”
- “If stored at room temperature [up to 30°C (86°F)], throw away unopened vial after 30 days.”
- “If stored at room temperature [up to 86°F (30°C)], throw away unopened vial after 30 days.”
- “If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze.”
- “Injection: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg/0.6 mL doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg/0.6 mL doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg/0.6 mL doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg/0.6 mL doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg/0.6 mL doses, or 60 mg/2.4 mL (25 mg/mL) for four 15 mg/0.6 mL doses in a multi-dose vial ( 3 )”
- “It can be used until the expiration date on the label if kept in the refrigerator.”
- “Store ZEPBOUND single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F).”
- “Store multi-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”
- “Store opened (in-use) vial in the original carton in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature [up to 30°C (86°F)].”
- “Store opened (in-use) vial in the original carton in the refrigerator at 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)].”
- “Store single-dose pen and single-dose vial in the refrigerator between 36°F to 46°F (2°C to 8°C).”
- “Store unopened vial in the refrigerator at 2°C to 8°C (36°F to 46°F).”
- “Store unopened vial in the refrigerator at 36°F to 46°F (2°C to 8°C).”
- “The unopened vial can be used until the expiration date on the label if kept in the refrigerator.”
- “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medication left in it.”
- “Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.”
- “Throw away single-dose pen or single-dose vial if not used within 21 days after removing from the refrigerator.”
- “Throw away the multi-dose vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if it still has medicine in it.”
-
October 24, 2025 (label version 28, published on DailyMed Nov 17, 2025; this version)
No longer in the label
“Inject ZEPBOUND subcutaneously in the abdomen, thigh, or upper arm.”“ZEPBOUND is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”
New in the label
- “Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.”
- “Inject ZEPBOUND under the skin (subcutaneously) of your stomach (abdomen), thigh, or another person should inject in the back of the upper arm.”
-
March 12, 2025 (label version 18, published on DailyMed Mar 21, 2025; this version)
No longer in the label
“4 x 2.5 mg/0.5 mL single-dose vials”“4 x 5 mg/0.5 mL single-dose vials”
-
December 20, 2024 (label version 15, published on DailyMed Jan 06, 2025; this version)
No longer in the label
“2.1 Recommended Dosage”“2.2 Recommendations Regarding Missed Dose”“Administer once weekly at any time of day, with or without meals.”“After 4 weeks, increase to 5 mg injected subcutaneously once weekly.”“Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )] .”“Increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.”“Inject subcutaneously in the abdomen, thigh, or upper arm.”“The maximum dosage is 15 mg subcutaneously once weekly.”“The maximum dosage of ZEPBOUND is 15 mg injected subcutaneously once weekly.”“The recommended maintenance dosages are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.”“The recommended maintenance dosages of ZEPBOUND in adults are 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”“The recommended starting dosage is 2.5 mg injected subcutaneously once weekly.”“The recommended starting dosage of ZEPBOUND is 2.5 mg injected subcutaneously once weekly.”
New in the label
- “2.1 Recommended Dose Escalation Schedule”
- “2.2 Recommended Maintenance and Maximum Dosage”
- “2.3 Recommendations Regarding Missed Dose”
- “Follow the dosage escalation below for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )] .”
- “Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved.”
- “Maximum Recommended Dosage”
- “Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly.”
- “Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly.”
- “Recommended Dose Escalation Schedule”
- “Recommended Maintenance Dosage”
- “Recommended Maintenance and Maximum Dosage”
- “The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.”
- “The recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly.”
- “The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
- “The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks.”
- “The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks.”
- “Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.”
-
October 23, 2024 (label version 12, published on DailyMed Nov 04, 2024; this version)
No longer in the label
“2.2 Recommended Dosage”“2.3 Recommendations Regarding Missed Dose”
New in the label
- “2.1 Recommended Dosage”
- “2.2 Recommendations Regarding Missed Dose”
- “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )] .”
- “For Studies 1 and 2, weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose).”
- “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
- “Weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose).”
-
May 23, 2024 (label version 8, published on DailyMed Aug 08, 2024; this version)
New in the label
- “4 x 2.5 mg/0.5 mL single-dose vials”
- “4 x 5 mg/0.5 mL single-dose vials”
Trulicity (dulaglutide)
7 label versions since January 2024; 2 changed the wording this site quotes, most recently May 28, 2025.
The per-pen card's lines
- Dose schedule (three card lines): changed in one version, most recently November 1, 2024.
- Dose increase (four card lines): changed in one version, most recently November 1, 2024.
- Missed dose (one card line): no change in this period.
- Storage out of fridge (two card lines): no change in this period.
-
May 28, 2025 (label version 56, published on DailyMed Jun 09, 2025; this version)
No longer in the label
“TRULICITY is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”
New in the label
- “Inject TRULICITY under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”
-
November 1, 2024 (label version 54, published on DailyMed Nov 14, 2024; this version)
No longer in the label
“If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage.”“Increase dosage to 1.5 mg once weekly for additional glycemic control.”“Increase the dosage to 1.5 mg once weekly for additional glycemic control.”
New in the label
- “After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control.”
- “Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )].”
- “If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] .”
Bydureon BCise (exenatide extended-release)
Discontinued FDA lists it as discontinued (Drugs@FDA, application NDA209210, checked November 10, 2026). Its label page is still on DailyMed. Drugs@FDA
Source: Drugs@FDA, via openFDA. Do not rely on openFDA to make decisions regarding medical care; check with your pharmacy.
2 label versions since January 2024; 1 changed the wording this site quotes, most recently May 28, 2025.
DailyMed did not serve the current label file on 2026-10-06 (HTTP 404 for https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5&type=zip); the record ends at the newest archived version.
The per-pen card's lines
- Dose schedule (two card lines): changed in one version, most recently May 28, 2025.
- Missed dose (one card line): no change in this period.
- Storage out of fridge (two card lines): no change in this period.
-
May 28, 2025 (label version 39, published on DailyMed Jun 05, 2025; this version)
No longer in the label
“BYDUREON BCISE is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”
New in the label
- “Inject BYDUREON BCISE under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”
- “It is acceptable to inject BYDUREON BCISE and insulin in the same body region, but the injections should not be adjacent to each other.”
- “Treatment with BYDUREON 2 mg once weekly (QW) resulted in mean HbA 1c reduction that was statistically significantly greater compared to sitagliptin 100 mg/day.”
- “Treatment with BYDUREON BCISE 2 mg once weekly (QW) resulted in a statistically significantly greater reduction in HbA 1c compared to BYETTA 10 mcg twice daily.”
Victoza (liraglutide)
4 label versions since January 2024; 3 changed the wording this site quotes, most recently October 14, 2025.
The per-pen card's lines
- Dose schedule (three card lines): changed in one version, most recently May 1, 2025.
- Dose increase (four card lines): changed in one version, most recently May 1, 2025.
- Missed dose (two card lines): no change in this period.
- Storage out of fridge (four card lines): changed in three versions, most recently October 14, 2025.
-
October 14, 2025 (label version 31, published on DailyMed Nov 17, 2025; this version)
No longer in the label
“Injection: 18 mg/3 mL (6 mg/mL) clear, colorless solution in a pre-filled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg.”“Store your Victoza pen at 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator at 36ºF to 46ºF (2°C to 8°C).”“Store your new, unused Victoza pen in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC).”
New in the label
- “Choose your injection site in either the stomach (abdomen), thigh, or upper arm (only if caregiver administered) and wipe the skin with an alcohol swab (See Figure M ).”
- “Injection: 18 mg/3 mL (6 mg/mL) clear, colorless solution in a prefilled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg.”
- “Let the injection site dry before you inject your dose.”
- “Store your Victoza pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator between 36ºF to 46ºF (2°C to 8°C).”
- “Store your new, unused Victoza pen in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”
- “When carrying the pen away from home, store the pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC).”
-
May 1, 2025 (label version 30, published on DailyMed Jun 12, 2025; this version)
No longer in the label
“Change (rotate) your injection site within the area you choose with each injection to reduce your risk of getting lumps under the skin (cutaneous amyloidosis).”“Choose your injection site in either the stomach (abdomen), thigh, or upper arm (only if caregiver administered) and wipe the skin with an alcohol swab (See Figure M ).”“If additional glycemic control is required, increase the dosage in 0.6 mg increments after at least one week on the current dosage.”“If more than 3 days have elapsed since the last VICTOZA dose, reinitiate VICTOZA at 0.6 mg once daily to mitigate any gastrointestinal symptoms associated with reinitiation of treatment.”“Let the injection site dry before you inject your dose.”“Store your Victoza pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator between 36ºF to 46ºF (2°C to 8°C).”“Store your new, unused Victoza pen in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”“The 0.6 mg once daily dosage is intended to reduce gastrointestinal symptoms [see Adverse Reactions (6.1)] during initial titration and is not effective for glycemic control in adults.”“Use caution when initiating or escalating doses of VICTOZA in patients with renal impairment (5.5) .”“Use caution when initiating or escalating doses of VICTOZA in patients with renal impairment [see Use in Specific Populations ( 8.6 )] .”“VICTOZA is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”“When carrying the pen away from home, store the pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC).”
New in the label
- “Change (rotate) your injection site with each injection.”
- “If additional glycemic control is required, increase the dosage in 0.6 mg increments after at least one week on the current dosage, to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] .”
- “If more than 3 days have elapsed since the last VICTOZA dose, reinitiate VICTOZA at 0.6 mg once daily to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”
- “Inject your dose of VICTOZA under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.”
- “Store your Victoza pen at 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator at 36ºF to 46ºF (2°C to 8°C).”
- “Store your new, unused Victoza pen in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC).”
- “The 0.6 mg once daily dosage is intended to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)] during initial titration and is not effective for glycemic control in adults.”
-
February 3, 2025 (label version 29, published on DailyMed Feb 24, 2025; this version)
No longer in the label
“Store your Victoza pen at 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator at 36ºF to 46ºF (2°C to 8°C).”“Store your new, unused Victoza pen in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC).”
New in the label
- “Choose your injection site in either the stomach (abdomen), thigh, or upper arm (only if caregiver administered) and wipe the skin with an alcohol swab (See Figure M ).”
- “Let the injection site dry before you inject your dose.”
- “Store your Victoza pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC), or in a refrigerator between 36ºF to 46ºF (2°C to 8°C).”
- “Store your new, unused Victoza pen in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).”
- “When carrying the pen away from home, store the pen at room temperature between 59ºF to 86ºF (15ºC to 30ºC).”
Saxenda (liraglutide)
5 label versions since January 2024; 3 changed the wording this site quotes, most recently February 25, 2026.
The per-pen card's lines
- Dose schedule (one card line): changed in one version, most recently May 1, 2025.
- Dose increase (one card line): changed in two versions, most recently October 14, 2025.
- Missed dose (one card line): no change in this period.
- Storage out of fridge (three card lines): no change in this period.
-
February 25, 2026 (label version 22, published on DailyMed Jun 15, 2026; this version)
No longer in the label
“If blood appears at the injection site, press lightly.”
New in the label
- “Choose your injection site and wipe the skin with an alcohol swab.”
- “If blood appears at the injection site, press lightly with a cotton ball or gauze.”
- “Let the injection site dry before you inject your dose.”
-
October 14, 2025 (label version 20, published on DailyMed Nov 17, 2025; this version)
No longer in the label
“Dose Escalation Schedule”
New in the label
- “Dosage Escalation Schedule”
-
May 1, 2025 (label version 19, published on DailyMed Jun 12, 2025; this version)
No longer in the label
“Change (rotate) your injection site within the area you choose with each injection to reduce your risk of getting lumps under the skin (cutaneous amyloidosis).”“For adults, the recommended dosage of SAXENDA is 3 mg daily, lower doses are for titration only.”“If more than 3 days have elapsed since the last SAXENDA dose, reinitiate SAXENDA at 0.6 mg daily and follow the dose escalation schedule in Table 3, to reduce the occurrence of gastrointestinal adverse reactions associated with reinitiation of treatment.”“If patients do not tolerate an increased dose during dose escalation, consider delaying dose escalation for approximately one additional week.”“Inject your dose of SAXENDA under the skin (subcutaneously) in your stomach area (abdomen), upper leg (thigh), or upper arm, as instructed by your healthcare provider.”“No dose adjustment is needed if changing the injection site and/or timing.”“Table 3: Dose Escalation Schedule”“The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9-1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.”“Then follow the dose escalation schedule in Table 3 to minimize gastrointestinal adverse reactions [see Adverse Reactions ( 6.1 )] .”“Use caution when initiating or escalating doses of SAXENDA in patients with renal impairment ( 5.6 ).”“Use caution when initiating or escalating doses of SAXENDA in patients with renal impairment [see Use in Specific Populations ( 8.6 )] .”
New in the label
- “Change (rotate) your injection site with each injection.”
- “Dosage escalation for pediatric patients may take up to 8 weeks.”
- “Dose Escalation Schedule”
- “For adults, the recommended dosage of SAXENDA is 3 mg daily, lower dosages are for titration only.”
- “If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1 , to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”
- “If patients do not tolerate an increased dose during dosage escalation, consider delaying dosage escalation for approximately one additional week.”
- “If pediatric patients do not tolerate an increased dose during dosage escalation, the dose may also be lowered to the previous level.”
- “No dosage adjustment is needed if changing the injection site and/or timing.”
- “SAXENDA is injected under the skin (subcutaneously) in your stomach area (abdomen), upper leg (thigh), or upper arm.”
- “The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 0.9 to 1.4 L/h with an elimination half-life of approximately 13 hours, making liraglutide suitable for once daily administration.”
- “Then follow the dosage escalation schedule in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.7 ), Adverse Reactions ( 6.1 )].”